Method for treating a perioheral arterial disease
US-2024425576-A1 · Dec 26, 2024 · US
Antagonistic human light-specific human monoclonal antibodies
US8974787B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8974787-B2 |
| Application number | US-201313889608-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 8, 2013 |
| Priority date | Aug 28, 2006 |
| Publication date | Mar 10, 2015 |
| Grant date | Mar 10, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-hLIGHT antibodies provided herein will ameliorate, neutralize or otherwise inhibit hLIGHT biological activity in vivo (e.g., the hLIGHT-mediated production or secretion of CCL20, IL-8 or RANTES from a cell expressing a hLIGHT receptor). Also provided herein is a method for the detection of hLIGHT in a sample as well as a method for ameliorating, neutralizing or otherwise inhibiting hLIGHT activity, e.g., in a human subject suffering from a disorder in which hLIGHT activity is detrimental.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating or alleviating one or more symptoms of an inflammatory bowel disorder in a human subject, comprising administering to the subject an effective amount of an antibody or antigen-binding fragment thereof that immunospecifically binds to human LIGHT (hLIGHT), wherein hLIGHT activity is inhibited by the antibody or antigen-binding fragment, and wherein the antibody or antigen-binding fragment thereof comprises: a variable heavy (VH) complemen…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8974787B2 cover?
- Provided herein are antibodies that immunospecifically bind to an hLIGHT polypeptide; isolated nucleic acids encoding the antibodies; vectors and host cells comprising nucleic acids encoding the antibodies; methods of making the antibodies; and a method of treating a hLIGHT-mediated disease in a subject comprising administering to the subject the antibodies. In preferred embodiments, the anti-h…
- Who is the assignee on this patent?
- Kyowa Hakko Kirin Co Ltd, Jolla Inst Allergy Immunolog
- What technology area does this patent fall under?
- Primary CPC classification C07K16/24. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 10 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).